SIGA TECHNOLOGIES INC
For the period ended May 7, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 7, 2024 · Filed May 7, 2024
Use the contents to explore the available documents and sections.
SIGA$3.10+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Recent Developments:
Recent Developments:
| • | On April 11, 2024, the Company’s partner in Japan, Japan Biotechno Pharma, announced that a new drug application for tecovirimat (TPOXX) was filed in Japan for the treatment of smallpox, mpox, cowpox, and complications due to vaccinia virus. |
|---|
| • | On April 1, 2024, the Company announced that it entered into an amendment of its international promotion agreement with Meridian Medical Technologies, LLC (Meridian). Effective June 1, 2024, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships. With the amendment, SIGA will have greater control over international promotion activities, which will enable the Company to meet global customers’ needs more effectively during these uncertain times of orthopox threats. |
|---|
| • | In first-quarter 2024, SIGA delivered approximately $24 million of oral TPOXX to a diverse mix of customers. Approximately $16 million of oral TPOXX was delivered to the U.S. government, including $15 million of deliveries to the U.S. Strategic National Stockpile and a $1 million delivery to the U.S. Department of Defense, and approximately $8 million of oral TPOXX was delivered to eight international customers. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.